Metacrine jumps as Wainwright starts with 'buy'

Metacrine

14/06/2021 11:48

** Drug developer's shares  MTCR.O  jump 8.7% premarket, set
to open at three-week high of $4.50
    ** Wainwright starts with "buy" rating, PT of $15; median PT
is $19.5 - Refinitiv data
    ** Brokerage says interim data for non-alcoholic
steatohepatitis (NASH) treatment candidate MET642, and drug
selection in Q4 represent key near-term catalysts
    ** Adds expansion into inflammatory bowel disease represents
substantial potential upside
    ** MTCR set for best session since early March
    ** Stock down 47% YTD, as of last close

 (Reporting by Susan Mathew in Bengaluru;)
 ((susan.mathew@thomsonreuters.com; +91-80-6287-2704;))